Digel Pharmaceuticals (688192.SH): There is uncertainty about whether the license agreement signed with AstraZeneca will be effective

Zhitong Finance App News, Dizhe Pharmaceutical (688192.SH) issued a stock price change announcement stating that recently, the company signed a “license agreement” with AstraZeneca UK Limited (“AstraZeneca”) to grant AstraZeneca the exclusive right to develop and commercialize Schwarzer® worldwide. As of the disclosure date of the announcement, the above transaction still needs to be submitted to the company's shareholders' meeting for review. The final entry into force requires meeting customary delivery conditions and obtaining necessary approval from relevant agencies such as anti-monopoly supervisory authorities in overseas jurisdictions. There is uncertainty about whether the “License Agreement” can take effect.